Clinical Trial Update: Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lumicitabine for RSV in hospitalized adults; study terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Lumicitabine (lumicitabine)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Respiratory Syncytial Viruses | Phase 2 | Status: TERMINATED | Results posted: 2019-12-24